Buprenorphine and Lapatinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Lapatinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both buprenorphine (a pain and addiction medicine) and lapatinib (a cancer medicine) can affect your heart's electrical rhythm. Doctors call this the QT interval. When two medicines that each stretch out that timing are taken together, the effect can add up and, in rare cases, lead to an irregular heartbeat.
I want to be honest with you: this concern is mostly theoretical, meaning we don't have strong proof it happens often. The good news is your care team can manage this. They may check your heart rhythm, watch your blood minerals like potassium and magnesium, and pick the safest plan for you. Please don't stop either medicine on your own. Just talk with your pharmacist or doctor first.
Effect: Additive QT-interval prolongation when buprenorphine is combined with lapatinib. Both agents independently carry QT-prolonging potential, so concurrent use may increase risk of QTc prolongation and, rarely, torsades de pointes.
Direction/mechanism: Pharmacodynamic (additive), not a metabolic prodrug interaction. Neither drug's activation is at issue here.
- Evidence: Theoretical; combined risk not quantified.
- Onset: Unspecified.
- Management: Avoid concomitant use where feasible. If co-prescribed, obtain baseline and follow-up ECGs, correct/monitor electrolytes (K+, Mg2+), and assess additional risk factors (bradycardia, CHF, congenital long-QT, recent AF conversion, digitalis therapy).
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
Concurrent administration of buprenorphine with agents capable of prolonging the QT interval should be avoided 342. It remains unknown what risk arises when buprenorphine is paired with other QT prolonging medications. When prescribing buprenorphine, clinicians should weigh these considerations in patients who present with risk factors including hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Both medicines can lengthen the QT interval, so your care team will weigh whether using them together is right for you, and they may choose an alternative when possible.
If you do take both, here is what typically happens and what you can do:
- Your team may check your heart rhythm with an ECG and monitor you more closely.
- They may check potassium and magnesium levels, since low levels raise the risk.
- Tell them about any history of fainting, palpitations, heart failure, slow heartbeat, or family heart-rhythm problems.
Keep taking both medicines as prescribed, and raise any dizziness, fainting, or irregular heartbeat with your pharmacist or doctor promptly.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Buprenorphine and Lapatinib together?
Buprenorphine and lapatinib can each prolong the QT interval, so combining them may add to that risk; the concern is theoretical, and your care team can manage it with ECG and electrolyte monitoring. Do not stop either medicine on your own, but discuss the combination with your pharmacist or doctor. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Lapatinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Lapatinib interaction managed?
Both medicines can lengthen the QT interval, so your care team will weigh whether using them together is right for you, and they may choose an alternative when possible. If you do take both, here is what typically happens and what you can do: Your team may check your heart rhythm with an ECG and monitor you more closely. They may check potassium and magnesium levels, since low levels raise the ris… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Lapatinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
Keep reading about Buprenorphine
Keep reading about Lapatinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist